Format

Send to

Choose Destination
Urologe A. 2017 Nov;56(11):1440-1444. doi: 10.1007/s00120-017-0510-5.

[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].

[Article in German]

Author information

1
Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland. martin.boegemann@ukmuenster.de.
2
Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland.
3
Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland.

Abstract

BACKGROUND:

Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and 223Ra), most of these patients still succumb to prostate cancer. Recently, 177lutetium prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy.

OBJECTIVES:

Establishment of the current position of 177Lu-PSMA-RLT in mCRPC in 2017.

MATERIALS AND METHODS:

Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on 177Lu-PSMA-RLT after PubMed-based research.

RESULTS:

In several larger retrospective studies, 177Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile.

CONCLUSIONS:

Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with 177Lu-PSMA-RLT in the treatment of mCRPC.

KEYWORDS:

Androgen receptor; Castration-resistant; Membrane antigen, prostate-specific; Radioligand therapy; Toxicity profile

PMID:
28986618
DOI:
10.1007/s00120-017-0510-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center